Alternatives to Viant + VLMS?
Based on BIEL’s open-market equity model, AI-powered platform, and global expansion goals—Viant + VLMS appear to be a uniquely synergistic duo. Some other considerations are:
1. REGENESIS Biomedical
Why it stands out: Specializes in non-drug pain relief using electromagnetic therapy—very aligned with ActiPatch’s PEMF technology.
Strategic fit: Already operates in the pain management space with FDA-cleared products.
Potential upside: Could bring clinical credibility and reimbursement pathways to wellness markets.
2. Relievant Medsystems
Why it stands out: Focuses on vertebrogenic pain treatment with the Intracept system.
Strategic fit: Deep expertise in spine-related pain could complement ActiPatch’s applications for back pain and neuropathy.
Potential upside: Strong clinical network and hospital access.
3. Cardiva Medical
Why it stands out: Known for vascular closure tech, but has experience commercializing medical devices.
Strategic fit: Could support ActiPatch’s expansion into surgical recovery and hospital systems.
Potential upside: Infrastructure for clinical deployment and post-op pain management.
Final Take
No single company currently matches the combined manufacturing scale of Viant and the digital equity agility of VLMS. However, REGENESIS Biomedical could be a dark horse—especially if BIEL wants to double down on clinical validation and pain-specific verticals.
Based on BIEL’s open-market equity model, AI-powered platform, and global expansion goals—Viant + VLMS appear to be a uniquely synergistic duo. Some other considerations are:
1. REGENESIS Biomedical
Why it stands out: Specializes in non-drug pain relief using electromagnetic therapy—very aligned with ActiPatch’s PEMF technology.
Strategic fit: Already operates in the pain management space with FDA-cleared products.
Potential upside: Could bring clinical credibility and reimbursement pathways to wellness markets.
2. Relievant Medsystems
Why it stands out: Focuses on vertebrogenic pain treatment with the Intracept system.
Strategic fit: Deep expertise in spine-related pain could complement ActiPatch’s applications for back pain and neuropathy.
Potential upside: Strong clinical network and hospital access.
3. Cardiva Medical
Why it stands out: Known for vascular closure tech, but has experience commercializing medical devices.
Strategic fit: Could support ActiPatch’s expansion into surgical recovery and hospital systems.
Potential upside: Infrastructure for clinical deployment and post-op pain management.
Final Take
No single company currently matches the combined manufacturing scale of Viant and the digital equity agility of VLMS. However, REGENESIS Biomedical could be a dark horse—especially if BIEL wants to double down on clinical validation and pain-specific verticals.
1
